Mpox vaccine uptake in the most endemic focus in Africa: a systematic review and meta-analysis (1970–2024)

Fabrice Zobel Lekeumo Cheuyem[1,2]*, Adidja Amani[1], Adamu Abubakar Umar[3], Chabeja Achangwa[4], Brian Ngongheh Ajong[5], Solange Dabou[2], Jessy Goupeyou-Youmsi[2], Guy Roger Pilo Ndibo[6], Rick Tchamani[7], Ethel Eno[8], Jonathan Hangi Ndungo[9], Saralees Nadarajah[3]

[1] Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé 1, Yaoundé, Cameroon

[2] Division of Health Policy and Research, Nkafu Policy Institute, Denis and Lenora Foretia Foundation, Yaoundé, Cameroon

[3] Department of Mathematics, University of Manchester, Manchester, UK

[4]. Department of Public Health, Faculty of Medical Sciences, University of West Indies, Cave Hill, Barbados

[5] Health Emergencies Programme, World Health Organization (WHO), Kinshasa, Democratic Republic of Congo

[6] Military Health Directorate, Ministry of Defence, Yaoundé, Cameroon

[7] Rosière Higher School of Health Sciences, Yaoundé, Cameroon

[8] Women in Global Health, Yaoundé, Cameroon

[9] Higher Institute of Medical Techniques, Bunia, Democratic Republic of Congo

Corresponding author's address: Fabrice Zobel Lekeumo Cheuyem, Department of Public Health, Faculty of Medicine & Biomedical Sciences, The University of Yaoundé 1, Yaoundé, Cameroon. Tel: +237 696 57 28 07; E-mail: zobelcheuyem@gmail.com; ORCID: 0000-0003-4047-8829.

Abstract

Background The Democratic Republic of Congo (DRC) represents the global epicenter of human Mpox. Vaccination remains the cornerstone of outbreak prevention as the disease continues to evolve from zoonotic spillover to sustained human-to-human transmission. However, comprehensive assessments of vaccination coverage trends across this vast, conflict-affected nation remain strikingly absent from the literature. This systematic review and meta-analysis provide the first pooled estimate of Mpox vaccine uptake and acceptance in the DRC spanning 54 years (1970-2024), capturing critical transitions including the post-smallpox eradication era and recent global outbreaks. Our study addresses temporal trends, geographic disparities, and the gap between vaccine acceptance and actual uptake in this high-risk setting.

Methods We conducted this review following PRISMA guidelines, systematically searching PubMed, ScienceDirect, and Google Scholar through February 2025. Using random-effects models, we calculated pooled estimates for vaccine uptake and acceptance rates, with prespecified subgroup analyses examining variations by: (1) period (1970-2000, 2000-2020, 2020-2024), (2) geographic region (Northwest endemic zone, Central/South zone, conflict-affected East), and (3) study design (surveillance vs. cross-sectional). We quantified heterogeneity using I^2 statistics and conducted meta-regression to identify predictors of vaccination coverage. Sensitivity analyses assessed the robustness of our findings.

Results Our analysis revealed a pooled Mpox vaccine uptake of just 30.26% (95% CI:14.11-46.41) with extreme heterogeneity (I^2 = 99.9%, p<0.001), indicating substantial variability across studies. Vaccine acceptance was higher at 54.55% (95% CI: 16.64- 92.46) demonstrating a concerning 24.29% intention-action gap. Temporal analysis showed catastrophic declines, from 35.31% coverage during 1970-2000 to just 1.79% in 2020-2024 - a 95% reduction post-global smallpox eradication. Geographic disparities were profound: Northwest endemic zones achieved 45.95% coverage compared to 9.78% in Central/South zones (p <0.001). Meta-regression identified no significant predictors of coverage (all p>0.05), suggesting complex, unmeasured determinants beyond conventional variables.

Conclusion Despite moderate acceptance rates, actual Mpox vaccination uptake in the DRC remains critically low, with worsening coverage in recent years and substantial regional inequities. These findings underscore the urgent need for context-specific interventions to bridge the intention-action gap in this high-risk setting.

Keywords Monkeypox, vaccine, uptake, acceptance, Democratic Republic of Congo, systematic review, meta-analysis

Background

Mpox, previously termed monkeypox, is a zoonotic disease stemming from the monkeypox virus [1]. Before 2022, its presence was confined mainly to secluded rainforest communities in the western and central parts of Africa [2]. The virus spreads through direct contact with infected animals or humans, including sexual or skin-to-skin contact, respiratory droplets, and contaminated objects like clothing, towels, and bedding [3,4]. The most recent Mpox outbreak was initially declared in the UK on May 7, 2022, and the contagion has disseminated to other continents beyond Africa [5]. Subsequently, the disease outbreak was declared as a Public Health Emergency of International Concern on July 23, 2022 [6]. There are two types of mpox, clade I and clade II. The ongoing global outbreak that started in 2022 is caused by clade II. The current epidemic in Central and Eastern Africa is caused by clade I mpox [7].

The Democratic Republic of Congo (DRC) has been the epicenter of human Mpox since the virus's first identification in 1970 [2]. The current resurgence in the Democratic Republic of the Congo (DRC) is linked to clade Ib, which is associated with more virulent manifestations of the disease, especially in pediatric populations and immunodeficient patients [8,9]. Mpox demonstrates considerable disease severity and has caused significant mortality in the Democratic Republic of Congo [10]. To address this disease severity and save lives, the global health and scientific community has developed and deployed several vaccines for this Mpox, which has the most endemic focus worldwide[1,11].

Developing new vaccines for widespread use against Mpox and its emerging strains is a critical preventive strategy in the ongoing battle against this dynamic infection [12]. The smallpox vaccine has undergone three generations of technological advancements, with only the second and third versions now licensed. Three orthopoxviral vaccines are available: ACAM2000, JYNNEOS, and LC16m8 [12]. A substantial genetic homology exists between smallpox and Mpox, evidenced by shared immunological epitopes and markers. Owing to this close relationship, various studies indicate that smallpox vaccines confer robust cross-immunity against Mpox [13]. Furthermore, hypotheses have been advanced that the observed escalation in Mpox prevalence is attributable to a progressively immunologically naive global population, stemming directly from the cessation of smallpox immunization campaigns [14].

Despite four decades of Mpox surveillance, vaccination coverage remains poorly characterized across this vast area , with multiple studies revealing variable temporal trends, geographic and healthcare access disparities especially in conflict-affected regions [1,2,11,15–21]. The DRC's health system - fragmented by decades of instability [5] - faces unique challenges in delivering vaccines to remote endemic zones like Equateur and Kivu [22]. Therefore, public health systems must take decisive action to prevent the global

spread of Mpox, particularly among vulnerable groups [23]. This action should include strengthening surveillance, improving vaccine access, and ensuring equitable distribution, especially in resource-poor settings like DRC [10]. To provide robust evidence on vaccine coverage and related socio-demographic trends. Our study addresses these knowledge gaps through the first comprehensive, half-century analysis of Mpox vaccination trends in the DRC. By synthesizing data from 1970 to 2024, we quantified temporal changes in coverage post-smallpox eradication, mapped regional inequities and assessed acceptance-uptake disparity. These insights will inform targeted vaccination strategies in this complex, high-priority setting.

Methods

Study design

This systematic review and meta-analysis examine the vaccination uptake and acceptance in the DRC between 1970 and 2024. The study was reported following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines [24].

Study setting

The DRC, the largest country in Sub-Saharan Africa, spans approximately 2,345,409 km² [25]. It shares borders with nine countries (Angola, Burundi, the Central African Republic, the Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda, and Zambia) [26]. The DRC comprises 26 provinces, including Kinshasa (the capital), Nord-Kivu, Sud-Kivu, Equateur, Tshuapa, and Bas-Huélé among others [10]. The health system is structured into three tiers: central, intermediate, and operational levels, with 519 health zones, 393 general referral hospitals, and 8,504 health areas delivering primary care [27]. With a population exceeding 105 million, the DRC has a median age of 16.7 years, a growth rate of 3.1%, and a life expectancy of 61.6 years [28]. The country faces recurrent infectious disease outbreaks, including Mpox, Ebola, Cholera, Measles and , Yellow fever, exacerbated by humanitarian crises linked to protracted civil unrest and armed conflict [29]. Socio-culturally, over 93% of the population identifies as Christian, with Catholics representing 42% [30]. These demographic, health, and geopolitical factors collectively shape the DRC's unique challenges in disease surveillance and outbreak response [31].

Eligibility criteria

This systematic review and meta-analysis included all published studies reporting Mpox vaccination uptake and acceptance in the DRC, irrespective of study design. We excluded studies with unclear outcome definitions and removed duplicate publications during screening. Only English- and French-language articles were eligible, with no restrictions on publication date.

Article searching strategy

Published research was identified through a systematic search on online databases, including PubMed, ScienceDirect, and Google Scholar. The search process involved examining titles and abstracts using a keywords and Medical Subject Headings (MeSH). Boolean operators ("AND" and "OR") were employed to refine the search, with terms including (monkeypox) OR (monkeypox virus) OR (human monkeypox) OR (Mpox) OR (mpox) OR (MPX) OR (epidemiological) OR (surveillance) OR (characteristics) OR (uptake) OR (vaccine) OR (vaccination) OR (acceptance) AND (DRC) OR (Democratic Republic of Congo) OR (Zaire). A manual search for additional publications not indexed in these databases was conducted to ensure comprehensive coverage. Furthermore, the reference lists of included studies were screened for relevant articles. The final search was completed on February 27, 2025.

Data extraction

Data was extracted from all eligible articles using a pre-designed Microsoft Excel 2016 form to collect study characteristics. This form captured the first author's name, study year, region, study design, study type, type of participant, setting, number of individuals willing to receive the vaccine, number of individuals who received the vaccine, and the sample size. Two authors independently assessed the relevance and quality of each article. Any disagreements between the reviewers were resolved through discussion with a third author to reach a consensus.

Data quality assessment

The Joanna Briggs Institute (JBI) quality assessment tool was used to evaluate the quality of the studies included [32]. Risk of bias was assessed using nine or ten criteria, depending on the study design. (1) For cross-sectional studies, criteria included: appropriateness of the sampling frame, use of a suitable sampling technique, adequate sample size, description of study subjects and setting, sufficient data analysis, use of valid methods for identifying conditions and measurements, use of appropriate statistical analysis, and an adequate response rate ($\geq$60%). (2) For case series, criteria included: standardized measurement and valid identification of the condition for all participants, consecutive and complete inclusion of participants, reporting of participant demographics and clinical information, reporting of outcomes or follow-up results, reporting of the presenting site(s)/clinic(s) demographic information, and statistical analysis appropriate for case series studies. Each criterion was scored as 1 (yes) or 0 (no or unclear). The overall risk of bias was categorized as low (>50%), moderate (>25-50%), or high ($\leq$25%).

Outcome measurement

The primary outcomes of this systematic review and meta-analysis were the Mpox vaccination uptake and the secondary outcome included the Mpox vaccine acceptance. The Mpox vaccine uptake and acceptance rate were calculated by dividing the number of people who received the vaccine and those who intended to receive it by the total number of participants.

Operational definition

The vaccination uptake refers to individuals who declared having received an Mpox vaccine or presented a Mpox vaccination card or a scar characteristic of the smallpox vaccine injection[15]. The Mpox acceptance refers to the intention, defined as the unconditional willingness to receive the free Mpox vaccine if offered[11,33].

Statistical analysis and synthesis

The I^2 statistic was used to assess the heterogeneity between studies, categorizing heterogeneity as low (<25%), moderate (25-75%), or high (>75%). Subgroup analyses were then conducted based on study period, region, setting, participant type, study design, and sample size, with a random-effects model employed when heterogeneity exceeded 50%. Furthermore, meta-regression explored whether study characteristics explained the variability in results. For subgroup analysis, the timeframe was divided into specific periods, including the smallpox vaccine era, 2010–2019: limited Mpox vaccine interest; 2020–2024: increased focus due to global outbreaks. The regions were grouped into geographical specific group including the Northwest endemic zone (historically high Mpox transmission zone encompassed Equateur, Tshuapa and Bas-Uélé); the Central/South endemic zone (moderate Mpox activity comprised Sankuru and Kasai Oriental); and the Easthern conflict affected zone (lower Mpox activity but high population movement included South Kivu, North Kivu and Tsopo). Only study variables with meaningful and practical categories were included in the analyses. Univariable and multivariable meta-regression models were used to assess whether the pooled estimate varied according to the selected explanatory variable categories. Statistical significance was set at a p-value of <0.05. All analyses were performed using the 'meta' package in R Statistics version 4.4.2 [34].

Publication bias and sensitivity test

Publication bias was assessed visually using a funnel plot. The symmetry of the inverted funnel shape suggested the absence of publication bias. Sensitivity analysis was conducted by iteratively excluding one study at a time to assess the robustness of the findings.

Results

A total of 185 entries were obtained through an online database search and a manual search. After removing 5 redundant entries, 181 distinct entries underwent title and abstract review, followed by a complete text evaluation for suitability. Ultimately, 18 research papers satisfied the inclusion standards and were incorporated into the meta-analysis (Fig. 1).

Studies selection

Fig. 1 PRISMA diagram flow of studies included in the meta-analysis

Characteristics of studies included

Eighteen studies carried out in community and hospital settings across the DRC between 1970 and 2024, were included in this comprehensive analysis. Most of these studies (n = 15) employed surveillance and investigation for data collection, focusing on the general population and healthcare workers to describe Mpox vaccination acceptance and uptake. Most of the studies (n = 16) presented a low risk of bias (Additional Files 1, Supplementary Table 1).

Mpox vaccine uptake

A random effects meta-analysis of 17 studies (n = 8498 participants) estimated an overall Mpox vaccination uptake rate of 30.26% (95% CI: 14.11–46.41), with substantial heterogeneity (I^2=99.9%, $p <$ 0.001). Study-specific rates ranged from 0% to 97.67% (Fig. 2).

Fig. 2 Pooled Mpox vaccination coverage estimate in DRC, 1970-2024

Mpox vaccine acceptance

A random effects meta-analysis of three studies (n = 5,388) yielded a pooled vaccine acceptance rate of 54.55% (95% CI: 16.64–92.46, n = 3 studies), with high heterogeneity (I^2=98.8%, $p <$ 0.0001). Individual study rates varied widely, from 18.92% (Nolen et al., 2013) [35] to 85.71% (Petersen, et al., 2014) [1], with the largest study (Petrichko et al., 2024) [11] reporting 61.00% (95% CI: 59.66–62.33) (Fig. 3).

Study	Events	Total		95%-CI	Weight
Nolen,2013	28	148		18.92 [12.95; 26.17]	34.0%
Petersen,2014	12	14		85.71 [57.19; 98.22]	31.7%
Petrichko,2024	3188	5226		61.00 [59.66; 62.33]	34.3%
Random effects model		**5388**		**54.55 [16.64; 92.46]**	**100.0%**

Heterogeneity: I^2 = 98.8%, τ^2 = 0.1091, $p <$ 0.0001

0   20   40   60   80   100

Subgroup analysis

The subgroup analysis revealed significant disparities in Mpox vaccination coverage across different periods, regions, and study designs in the DRC (1970–2024). The vaccination coverage was highest in earlier decades (35.31% in 1970–2000; 38.00% in 2000–2020) but plummeted to 1.79% during 2020–2024, suggesting recent declines in vaccination efforts. Geographically, Equateur (51.10%, n=2 studies) and Bas-Uélé (92.96%, n=1 study) had notably high coverage, while Sankuru (9.00%) and Tshopo (3.48%) lagged. Nationwide studies reported highly variable estimates (51.23%, 95% CI: 0–100%, n = 2 studies). Surveillance and investigation-based studies showed higher coverage (33.98%) than cross-sectional designs (2.87%), though extreme heterogeneity ($I2 = 84.9\%, p < 0.006$) persisted across most subgroups, underscoring the influence of contextual factors like endemicity zones (45.95% in Northwest vs. 9.78% in Central/South) and participant type (50% in healthcare workers vs. 21.62% in mixed populations) (Table 1).

Table 1 Subgroup analysis of Mpox vaccination coverage in DRC, 1970-2024

Subgroup	Sample size	Coverage (%)	95% CI limits		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2 (%)	p-value
Study period[2]							
1970-2000	5409	35.31	9.76	60.86	8	99.9	⊡0.001
2000-2020	2080	38.00	10.33	65.67	6	99.4	⊡0.001
2020-2024	1009	1.79	0.00	3.88	3	89.7	⊡0.001
Region							
Equateur	1170	51.10	0.00	100.00	2	99.7	⊡0.001
South Kivu	1916	13.39	0.00	37.46	3	99.7	⊡0.001
Kasai Oriental	423	11.22	0.00	22.86	2	86.6	0.006
Sankuru	844	9.00	0.00	20.36	2	88.2	0.004
Tshuapa	1219	23.54	3.07	44.00	3	90.7	⊡0.001
Kivu (North and South)	30	53.33	34.33	71.66	1	-	-
Bas-Uélé	71	92.96	84.33	97.67	1	-	-
Tshopo	460	3.48	2.00	5.59	1	-	-
Nationwide	2365	51.23	0.00	100.00	2	99.99	⊡0.001
Zone[3]							
Northwest endemic zone	2460	45.95	13.54	78.36	6	99.99	⊡0.001
Central/South endemic zone	1267	9.78	3.13	16.43	4	84.9	⊡0.001
Eastern conflict-affected zone	2406	18.49	0.00	39.25	5	99.5	⊡0.001
Nationwide	2365	51.23	0.00	100.00	2	99.99	☐0.001
Design							
Cross-sectional	768	2.87	1.69	4.05	2	0.2	0.317
Surveillance and investigation	7730	33.98	16.46	51.51	15	100	☐0.001
Setting							
Community	8190	32.04	15.24	48.85	16	100	☐0.001
Hospital	308	2.27	0.92	4.63	1	-	-
Participant							
General population	8336	29.70	11.66	47.74	15	100	☐0.001
General population and Healthcare worker	148	21.62	15.28	29.13	1	-	-

Healthcare worker	14	50	23.04	76.96	1	-	-
Sample size							
▢100	321	39.29	12.68	65.89	6	98.8	▢0.001
100+	8177	25.53	4.89	46.17	11	100	▢0.001

[1] Random effects model; CI: Confidence Interval; [2] 1980 –2000: smallpox vaccine era; 2010–2019: limited mpox vaccine interest; 2020–2024: increased focus due to global outbreaks; [3] Northwest endemic zone (historically high Mpox transmission zone) = Equateur, Tshuapa and Bas-Uélé; Central/South endemic zone (moderate Mpox activity) = Sankuru and Kasai Oriental; Easthern conflict affected zone (lower Mpox activity but high population movement)= South Kivu, North Kivu and Tsopo.

Meta-regression analysis

The meta-regression analysis found no statistically significant predictors of Mpox vaccination coverage in the DRC (1970–2024). While the study year showed a marginal negative trend in univariate analysis (β = -0.0545, p = 0.078), suggesting a possible decline in coverage over time, this association was not significant after adjustment (β = -0.0396, p = 0.3342). Similarly, region, study design (surveillance vs. cross-sectional), setting (hospital vs. community), and sample size demonstrated no significant effects in either univariate or multivariate models (p > 0.1 for all) (Table 2).

Table 2 Meta-regression analysis of Mpox vaccination coverage and acceptance in DRC, 1970-2024

Estimate	Moderator	Univariate		Multivariate	
		Unadjusted coefficient (β)	*p*-value	Adjusted coefficient (β)	*p*-value
Vaccination uptake					
Study year	Year	-0.0545	0.078	-0.0396	0.3342
Region	Region vs. Nationwide	-1.6282	0.341	-1.3101	0.5036
Design	SIR vs. Cross-sectional	2.5622	0.115	0.6293	0.8139
Setting	Hospital vs. Community	-2.6276	0.258	-0.4380	0.8944
Sample size	▢100 vs. 100+	1.2291	0.291	-1.3843	0.2933

[1] Redundant predictor dropped from the model; VZV: Varicella-zona virus; HIV: Human immunodeficiency virus; Others included Sankuru and Tshuapa Regions; SIR: Surveillance and investigation report (Case series)

Publication bias

While the left shift of the funnel plot suggested potential publication bias, Egger's test (p = 0.203) and Begg's test (p = 0.249) did not indicate any statistically significant bias (Fig. 3).

Fig. 3 Funnel plot with pseudo 95% confidence limits and tests assessing the publication bias studies included

Sensitivity test analysis

Sensitivity analysis indicated that the pooled Mpox vaccination coverage estimate was robust to the exclusion of most single studies. However, removing Ladnyj *et al.*,1970 or Jezek *et al.*,1984 reduced the coverage to approximately 12-14%, while omitting Vakaniaki *et al.*, 2024 increased it to 39.54% [15,17,18].

Study		Events	95%-CI	P-value	Tau2	Tau	I2
Omitting Landnyj,1970		13.70	[13.28; 14.12]	.	0.0915	0.3025	99.9%
Omitting Breman,1979		20.46	[20.06; 20.85]	.	0.1177	0.3430	100.0%
Omitting Mutombo,1982		20.00	[19.60; 20.40]	.	0.1208	0.3475	100.0%
Omitting Jezek,1985		20.53	[20.13; 20.93]	.	0.1187	0.3445	100.0%
Omitting Jezek,1984		12.10	[11.68; 12.52]	.	0.0943	0.3070	99.9%
Omitting Mwamba,1997		20.43	[20.04; 20.83]	.	0.1201	0.3465	100.0%
Omitting Hutin,1997		20.44	[20.04; 20.84]	.	0.1196	0.3459	100.0%
Omitting Aplogan,1997		20.80	[20.40; 21.21]	.	0.1170	0.3421	100.0%
Omitting Rimoin,2007		21.98	[21.56; 22.39]	.	0.1162	0.3409	100.0%
Omitting Nolen,2013		20.42	[20.03; 20.82]	.	0.1206	0.3473	100.0%
Omitting Petersen,2014		20.42	[20.02; 20.82]	.	0.1181	0.3436	100.0%
Omitting McCollum,2014		20.41	[20.01; 20.81]	.	0.1173	0.3426	100.0%
Omitting Whitehouse,2015		21.05	[20.64; 21.46]	.	0.1181	0.3436	100.0%
Omitting Mande,2019		20.10	[19.70; 20.50]	.	0.0931	0.3051	100.0%
Omitting Brosius,2024		21.53	[21.12; 21.94]	.	0.1156	0.3401	100.0%
Omitting Kombozi,2024		21.44	[21.03; 21.85]	.	0.1161	0.3408	100.0%
Omitting Vakaniaki,2024		39.54	[38.98; 40.09]	.	0.1147	0.3387	99.9%
Common effect model		**20.43**	**[20.03; 20.83]**	.	**0.1135**	**0.3369**	**99.9%**

0 20 40 60 80 100

Fig. 4 Sensitivity analysis of the pooled Mpox vaccination coverage in DRC, 1970-2024

Discussion

This systematic review and meta-analysis were primarily conducted to determine the Mpox vaccine uptake rate in the world's most endemic focus. It synthesized data from 18 studies to provide a comprehensive overview in the DRC from 1970 to 2024.

Vaccine uptake

This meta-analysis comprehensively assesses Mpox vaccination coverage in the DRC from 1970 to 2024, revealing critical insights into its temporal trends, regional disparities, and methodological challenges. The pooled estimate (30.26%, 95% CI: 14.11–46.41) and subgroup analyses demonstrated high heterogeneity ($I^2 > 99.9\%$), reflecting wide variability in coverage across regions, periods, and study designs. Our results corroborated findings from a global meta-analysis of Mpox vaccine uptake, which revealed a pooled rate of 30.9% (95% CI: 21.0–41.7), but this was higher than that of the WHO African region at 5.0% (95% CI: 3.7–6.7) [33]. This highlights a substantial disparity in vaccine coverage between the African region and the global average.

Our analysis revealed a notable temporal trend in Mpox vaccination coverage within the DRC. Coverage was substantially higher in studies conducted between 1970 and 2000, with a pooled estimate of 35.31%. However, this figure plummeted to a mere 1.79% in studies conducted post-2020. This represents a dramatic reduction of over 95% in estimated vaccination coverage, signaling a critical shift in the landscape of Mpox prevention efforts. This decline may be associated with challenges in vaccine supply chains, reduced access to healthcare facilities, and a diversion of resources to outbreak response [36,37]. This likely contributed to the substantial decrease in routine vaccination activities. The significant drop in Mpox vaccination coverage post-2020 seriously affects public health in the DRC. Reduced population immunity increases the risk of future outbreaks, potentially with greater severity and wider spread, particularly if healthcare systems remain strained [10,38].

To explore potential geographical variations in Mpox vaccination coverage, we conducted a stratified analysis across three distinct zones within the DRC: the Northwest endemic zone, the Central/South endemic zone, and the Eastern conflict-affected zone. Our study revealed significant disparities in the pooled estimates across these regions. The Northwest endemic zone exhibited the highest estimated coverage/acceptance at 45.95%, while the Central/South endemic zone showed a considerably lower estimate of 9.78%. The Eastern conflict-affected zone presented an intermediate estimate of 18.49%. The higher estimated coverage in the Northwest endemic zone could be attributed to the region's more extended history with Mpox outbreaks, potentially leading to greater community awareness and established vaccination programs over time [2,15]. The lower coverage observed in the Central/South endemic zone, or the Eastern conflict-affected zone likely reflects differing healthcare priorities or access challenges compared to the Northwest. The complex interplay

of conflict-related disruptions to healthcare access alongside potential targeted interventions by humanitarian organizations may also explain these findings [16,19].

Future research should prioritize comprehensive investigations into the intricate interplay of healthcare infrastructure, community engagement strategies, and the pervasive impact of conflict on vaccination efforts across different regions. By meticulously dissecting these nuances, we can pave the way for **developing and implementing** targeted, equitable, and ultimately more effective strategies to strengthen immunization programs in DRC.

Vaccine acceptance

Our study's pooled Mpox vaccine acceptance rate was 54.55% (95% CI: 16.64-92.46), consistent with a global meta-analysis and an African multinational study reporting acceptance rates between 51.1% and 74.4% [5,33]. However, we identified a substantial discrepancy between vaccine acceptance (54.55%) and actual uptake (30.26%), revealing a critical implementation gap in Mpox vaccination programs. This disparity likely results from multiple factors, including temporal variations in study periods and uneven vaccine availability across different settings.

Comprehensive vaccination strategies are urgently needed to address this gap and convert vaccination intentions into actual coverage[11,39]. Such efforts are vital as individuals who initially intend to vaccinate but remain unvaccinated are at high risk of vaccine hesitancy or refusal over time [40,41]. Therefore, effective public health interventions must extend beyond promoting acceptance to include practical measures that improve vaccine accessibility, overcome logistical challenges, and strengthen community trust in vaccination programs.

Closing this implementation gap is especially crucial given Mpox's severe health consequences in the DRC, where vulnerable populations - including children and immuno-compromised individuals - experience high rates of morbidity and mortality. The clinical management of Mpox is further complicated by frequent coinfections with varicella-zoster virus, underscoring the urgent need for effective vaccination programs [10,42].

Strength and limitations

This review has several limitations. The small number of included studies for Mpox vaccine acceptance (□3). Additionally, the small sample sizes in some subgroup analyses resulted in wide confidence intervals, limiting the precision of the findings. The predominance of non-probabilistic surveillance data might limit the inference. In addition, the vaccination status relied primarily on individual reports or the presence of a scar of vaccination instead of the presentation of a vaccination card testifying to the reception of the vaccine. Despite these limitations, this systematic review and meta-analysis provide a comprehensive synthesis of

Mpox vaccination trends in the DRC over five decades, offering valuable insights into temporal patterns, geographic disparities, and implementation gaps through robust analysis of 18 diverse studies.

Conclusions

This systematic review revealed critical findings about Mpox vaccination in the DRC. A dramatic decline in coverage from 1970 to 2024 signals systemic failures in maintaining population immunity, particularly after the global strategy to eradicate smallpox. The stark disparity between vaccine acceptance and actual uptake highlights substantial implementation gaps beyond willingness. Geographic inequities, with Northwest zones achieving higher coverage than Central and armed conflict regions, underscore how conflict and healthcare access shape vaccination outcomes. Two main priorities identified include targeted campaigns for underserved areas like Sankuru and Tshopo provinces, and operational research to convert acceptance into uptake through community-engaged delivery models. As Mpox continues to evolve and poses a public health threat in this endemic heartland, these results provide both a warning and a roadmap to close the vaccination gaps before the outbreak escalates beyond control. Future success will require integrating these empirical findings with local knowledge to build equitable, sustainable protection for all communities.

Abbreviations

CI: Confidence interval

DRC: Democratic Republic of Congo

HCW: Healthcare worker

MeSH: Medical subject headings

Mpox: Monkeypox

PRISMA: Preferred reporting items for systematic reviews and meta-analysis

Declarations

Ethical approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: The sources of data supporting this systematic review are available in the reference. All data generated or analyzed during this study are included in this published article and supplemental material.

Competing interests: All authors declare no conflicts of interest and have approved of the final version of the article.

Funding source: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Author contributions: F.Z.L.C. conceived the original idea of the study. F.Z.L.C and C.A. conducted the literature search. F.Z.L.C., C.A. and C.T.A. selected the studies, extracted the relevant information, and synthesized the data. F.Z.L.C., A.A.U. and S.N. performed the analyses. F.Z.L.C. wrote the first draft of the manuscript. All authors critically reviewed and revised successive drafts of the manuscript. All authors read and approved of the final manuscript.

Acknowledgements: None.

References

1.   Petersen BW, Kabamba J, McCollum AM, Lushima RS, Wemakoy EO, Muyembe Tamfum JJ, *et al.* Vaccinating against monkeypox in the Democratic Republic of the Congo. *Antiviral Res.* 2019; 162:171–7.

2.   Breman JG, Kalisa-Ruti null, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bull World Health Organ.* 1980;58(2):165–82.

3.   Grose C. Surveillance of Nigerian children suggests that varicella may be a risk factor for acquisition of monkeypox. *Front Public Health.* 2023; 11:1140956.

4.   Fetensa G, Tolossa T, Besho M, Yadesa G, Gugsa J, Tufa DG, *et al.* Willingness to take Mpox vaccine and associated factors among health professionals in Ethiopia: A cross-sectional study. *Vaccine.* 2025;49:126822.

5.   Du M, Deng J, Yan W, Liu M, Liang W, Niu B, *et al.* Mpox vaccination hesitancy, previous immunisation coverage, and vaccination readiness in the African region: a multinational survey. *eClinicalMedicine.* 2025; 80:103047.

6.   Sah R, Padhi BK, Siddiq A, Abdelaal A, Reda A, Ismail Lashin B, *et al.* Public Health Emergency of International Concern declared by the World Health Organization for Monkeypox. *Glob Secur Health Sci Policy.* 2022;7(1):51–6.

7.   Ongoing Clade II Mpox Global Outbreak [Internet]. CDC, Atlanta. 2025 [Accessed 2025 May 20]. Available from: https://www.cdc.gov/mpox/outbreaks/2022/index-1.html

8.   Olawade DB, Wada OZ, Fidelis SC, Oluwole OS, Alisi CS, Orimabuyaku NF, *et al.* Strengthening Africa's response to Mpox (monkeypox): insights from historical outbreaks and the present global spread. *Sci One Health.* 2024; 3:100085.

9.   Mitjà O, Alemany A, Marks M, Mora JIL, Rodríguez-Aldama JC, Silva MST, *et al.* Mpox in people with advanced HIV infection: a global case series. *The Lancet.* 2023;401(10380):939–49.

10.   Cheuyem FZL, Zemsi A, Ndungo JH, Achangwa C, Takpando-le-grand DR, Goupeyou-Youmsi J, *et al.* Mpox severity and mortality in the most endemic focus in africa: a systematic review and meta-analysis (1970-2024). *medRxiv*; 2025. doi: 10.1101/2025.04.07.25325410v2.

11. Petrichko S, Kindrachuk J, Nkamba D, Halbrook M, Merritt S, Kalengi H, *et al.* Mpox Vaccine Acceptance, Democratic Republic of the Congo. *Emerg Infect Dis.* 2024;30(12):2614–9.

12. Shafaati M, Forghani S, Shahsavand Davoudi A, Samiee R, Mohammadi K, Akbarpour S, *et al.* Current advances and challenges in mpox vaccine development: a global landscape. *Ther Adv Vaccines Immunother.* 2025; 13:25151355251314339.

13. Wang X, Gu Z, Sheng S, Song R, Jin R, Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China, *et al.* The Current State and Progress of Mpox Vaccine Research. *China CDC Wkly.* 2024;6(7):118–25.

14. Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. *Lancet Infect Dis.* 2022;22(12):e349-58.

15. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. *Bull World Health Organ.* 1972;46(5):593–7.

16. Brosius I, Vakaniaki EH, Mukari G, Munganga P, Tshomba JC, Vos ED, *et al.* Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study. *The Lancet.* 2025;405(10478):547–59.

17. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O''Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, *et al.* Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nat Med.* 2024;30(10):2791–5.

18. Jezek Z, Marennikova SS, Mutumbo M, Nakano JH, Paluku KM, Szczeniowski M. Human Monkeypox: A Study of 2,510 Contacts of 214 Patients. *J Infect Dis.* 1986;154(4):551–5.

19. McCollum AM, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, *et al.* Human Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo. *Am Soc Trop Med Hyg.* 2015;93(4):718–1.

20. Whitehouse ER, Bonwitt J, Hughes CM, Lushima RS, Likafi T, Nguete B, *et al.* Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. *J Infect Dis.* 2021;223(11):1870–8.

21. Dieu-Merci. KY, Singa Valentin. B, Ley. BL, Antoine. ET, Guild. AK, Lwanga. K, *et al.* MPOX: EPIDEMIOLOGICAL PROFILE AND FACTORS ASSOCIATED WITH ITS EMERGENCE IN THE ISANGI TERRITORY, DEMOCRATIC REPUBLIC OF CONGO. *Int J Appl Sci Eng Rev.* 2024;5(5):27–43.

22. Makali SL, St Louis P, Karemere H, Wautié A, Pavignani E, Eboma CM, *et al.* Exploring the inherent resilience of health districts in a context of chronic armed conflict: a case study in Eastern Democratic Republic of the Congo. *Health Res Policy Syst.* 2024;22(1):1–15.

23. Djuicy DD, Selekon B, Malaka C, Soumah A, Adjogoua E, Kadjo H, *et al.* Strengthening Africa's resilience to Mpox: Preparedness and response initiatives of the Pasteur network. *J Public Health Afr.* 2025;16(1):1026.

24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Med.* 2009;6(7):e1000097.

25. Congo, Democratic Republic of the. In: The World Factbook. Central Intelligence Agency. 2023. https://www.cia.gov/the-world-factbook/countries/congo-democratic-republic-of-the/. Accessed 2023 Oct 30.

26. Tati G. Territory and border crossing for livelihoods among (voluntary and forced) migrants from DRC to Swaziland: the re-imagining of a borderless spatial system. In: Udelsmann Rodrigues C, Tomàs J, editors. Crossing African Borders: Migration and Mobility. Lisboa: Centro de Estudos Internacionais; 2012. p. 126–44. (ebook'IS).

27. République démocratique du Congo - Plan national de développement sanitaire recadré pour la période 2019-2022□: Vers la Couverture sanitaire universelle. DRC. 2018. https://www.ilo.org/dyn/natlex/natlex4.detail?p_isn=111796&p_lang=fr. Accessed 2023 Oct 30.

28. Democratic Republic of the Congo. WHO, Geneva. 2024. https://data.who.int/countries/180. Accessed 2025 Mar 27.

29. Amani A, Bene ACM, Lungoyo CL, Mukoka AK, Cheuyem FZL, Mpinganjira S, *et al.* The Struggle to Vaccinate: Unveiling the Reality of the first year of Covid-19 Vaccination in the Democratic Republic of Congo. *medRxiv*; 2024. doi: 10.1101/2024.01.03.24300795v1.

30. Overview. World Bank. 2023. https://www.worldbank.org/en/country/drc/overview. Accessed 2025 May 07.

31. Democratic Republic of the Congo situation. UNHCR, Global Focus, Geneva. 2024. https://reporting.unhcr.org/operational/situations/democratic-republic-congo-situation. Accessed 2025 Apr 6.

32. JBI Critical Appraisal Tools. The Joanna Briggs Institute, Adelaide. 2017. https://jbi.global/critical-appraisal-tools. Accessed 2024 Dec 3.

33. Sulaiman SK, Isma'il Tsiga-Ahmed F, Musa MS, Makama BT, Sulaiman AK, Abdulaziz TB. Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis. *Commun Med.* 2024;4(1):136.

34. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2024. https://www.R-project.org/. Accessed 2024 Dec 19.

35. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, *et al.* Extended Human-to-Human Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo. *Emerg Infect Dis.* 2016;22(6):1014–21.

36. Adigun OA, Okesanya OJ, Ahmed MM, Ukoaka BM, Lucero-Prisno DE, Onyeaghala EO, *et al.* Syndemic Challenges: Addressing the Resurgence of Mpox Amidst Concurrent Outbreaks in the DRC. Zheng C, editor. *Transbound Emerg Dis.* 2024;2024(1):1962224.

37. Mpox. WHO, Geneva. 2024. https://www.who.int/news-room/fact-sheets/detail/mpox. Accessed 2025 Apr 27.

38. Abdelouahed M, Yateem D, Amzil C, Aribi I, Abdelwahed EH, Fredericks S. Integrating artificial intelligence into public health education and healthcare: insights from the COVID-19 and monkeypox crises for future pandemic readiness. *Front Educ.* 2025; 10:1518909.

39. Cheuyem FZL, Amani A, Nkodo ICA, Boukeng LBK, Edzamba MF, Nouko A, *et al.* COVID-19 vaccine acceptance and hesitancy in Cameroon: a systematic review and meta-analysis. *BMC Public Health.* 2025;25(1):1035.

40. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. *Nat Hum Behav.* 2021;5(3):337–48.

41. Cheuyem FZL, Amani A, Achangwa C, Ajong BN, Minkandi CA, Zeh MMMK, *et al.* COVID- 19 vaccine uptake and its determinants in Cameroon: a systematic review and meta-analysis (2021–2024). *BMC Infect Dis.* 2025;25(1):525.

42. Cheuyem FZL, Asahngwa C, Bakari WN, Achangwa C, Goupeyou-Youmsi J, Ajong BN, *et al.* Mpox clinical features and varicella-zoster virus coinfection in the Democratic Republic of Congo: a systematic review and meta-analysis (1970-2024) . *medRxiv;* 2025. doi: 10.1101/2025.05.02.25326902v1.

43. Mutombo M, Jezek Z, Arita I, Jezek Z. HUMAN MONKEYPOX TRANSMITTED BY A CHIMPANZEE IN A TROPICAL RAIN-FOREST AREA OF ZAIRE. *Lancet Lond Engl.* 1983;321(8327):735–7.

44. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical Features of 282 Patients. *J Infect Dis.* 1987;156(2):293–8.

45. Mwanba PT, Tshioko KF, Moudi A, Mukinda V, Mwema GN, Messinger D, *et al.* Human monkeypox in Kasaï Oriental, Zaire (1996-1997). *Eurosurveillance.* 1997;2(5):33–5.

46. Hutin YJF, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, *et al.* Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Infect Dis.* 2001;7(3):434–8.

47. Aplogan A, Mangindula V, Muamba P, Mwema G, Okito L, Pebody R, *et al.* Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. *MMWR Morb Mortal Wkly Rep.* 1997;46(49):1168–71.

48. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, *et al.* Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci.* 2010;107(37):16262–7.

49. Mande G, Akonda I, Weggheleire AD, Brosius I, Liesenborghs L, Bottieau E, *et al.* Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions. *Int J Infect Dis.* 2022; 122:647–55.

Supplementary Table 1 Characteristic of studies assessing Mpox vaccination in DRC, 1970-2024

Author	Study Year[1]	Region	Setting	Study population	Study type	Sampling	Risk of bias	Outcome of interest	Sample size vaccination survey	Summary of findings
Ladnyj et al. [15]	1970	Equateur	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	1132	The unvaccinated young patient's relatives and most villagers showed signs of smallpox vaccination or previous infection.
Breman et al. [2]	1979	Equateur	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	38	Of the 47 reported cases in Central and West Africa, 38, representing the vast majority, occurred in Zaire. These cases, largely in children under 10, presented with a 17% case-fatality rate.
Mutombo et al. [43]	1982	South Kivu	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	1367	The rash's onset was consistent with chimpanzee transmission, but the primary monkeypox reservoir remained unknown.
Jezek et al. [18]	1984	Nationwide	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	2083	A study of 2,510 contacts of monkeypox patients revealed a significant number of secondary cases, primarily in children, with waning immunity observed in vaccinated individuals, though vaccination still offered considerable protection.
Jezek et al. [44]	1985	Nationwide	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	282	unvaccinated individuals, particularly young children, experienced an 11-15% case-fatality rate, while vaccinated individuals showed no deaths and altered disease presentation.
Mwamba et al. [45]	1997	Kasai Oriental	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	84	The 1996-97 investigation suggested most monkeypox cases resulted from person-to-person transmission, a shift from earlier reports of primarily animal-to-human spread.
Hutin et al. [46]	1997	Sankuru	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	84	This outbreak presented with notable attack and case-fatality rates. The cessation of smallpox vaccination in 1983, following global eradication, contributed to an increased population susceptibility to monkeypox.
Aplogan et al. [47]	1997	Kasai Oriental	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	339	There was a high prevalence of Mpox among children and a mix of primary and secondary transmission patterns across numerous villages. The outbreak was localized outbreaks and travel, close contact within households and neighborhoods facilitated the secondary case transmission.
Rimoin et al. [48]	2007	Sankuru	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	760	This study revealed a dramatic increase in cases, likely due to the cessation of smallpox vaccination and the subsequent rise in a immunologically naive population.
Nolen et al. [35]	2012	Tshuapa	Hospital	General population and healthcare worker	SIR	Non-probabilistic	Low	Vaccine acceptance and uptake	148	Half of possible cases were lab-confirmed monkeypox. 50% household attack rate, multiple family transmissions, and a mean 8-day incubation period (4-14 days) were observed.
Petersen et al. [1]	2014	Tshuapa	Community	Healthcare worker	SIR	Non-probabilistic	Low	Vaccine uptake and acceptance	14	These findings suggest that while a smallpox vaccination scar may offer some protection against monkeypox, healthcare workers remain at risk of infection. The presence of co-infections further complicates the picture.
McCollum et al. [19]	2014	Kivu (North and South)	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	30	Report of the first confirmed cases of monkeypox (Mpox) in forested areas of North and South Kivu Provinces, which aligns with ecological predictions for suitable Mpox transmission zones.
Whitehouse et al. [20]	2014	Tshuapa	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	1057	Increased incidence compared to previous decades, likely due to waning smallpox immunity. While males generally had higher infection rates, females reported frequent contact with symptomatic individuals. Animal exposures were most common in males.
Mande et al. [49]	2019	Bas-Uélé	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	71	Among 77 suspected cases, PCR revealed 27.3% monkeypox, 58.4% chickenpox, and 14.3% negative. Monkeypox cases showed distinct skin lesions.

Brosius et al. [16]	2024	South Kivu	Hospital	General population	Cross-sectional	Non-probabilistic	Moderate	Vaccine uptake	308	Most suspected cases were PCR-positive for Mpox. Most cases reported contact with known Mpox, primarily spouses/partners in adults and family in children. Genital lesions were common in adults. Hospitalized mortality was low.
Petrichko et al. [11]	2024	Nationwide	Community	General population	Cross-sectional	Non-probabilistic	Moderate	Vaccine acceptance	5226	In the DRC, 61% accepted a Mpox vaccine, with higher rates among healthcare workers and in endemic regions.
Kombozi et al. [21]	2024	Tshopo	Community	General population	Cross-sectional	Probabilistic	Low	Vaccine uptake	460	Occupational activities, such as hunting and agriculture, alongside economic vulnerability and direct exposure to infected animals or individuals, play a significant role in Mpox transmission. These results underscore the complex interplay between human behavior, environmental interaction, and disease spread.
Vakaniaki et al. [17]	2024	South Kivu	Community	General population	SIR	Non-probabilistic	Low	Vaccine uptake	241	The Mpox outbreak in eastern DRC was caused by a distinct Clade I Mpox lineage, differing from historical zoonotic patterns. The outbreak, predominantly affected young adults including a significant proportion of female sex workers, suggests a shift towards human-to-human transmission, potentially involving sexual contact.

[1] Date of study completion; SIR: Surveillance and Investigation Report (Case series); HCW; Healthcare Worker; DRC: Democratic Republic of Congo; PCR: Polymerase Chain Reaction